Yellow fever vaccine supply: a possible solution

@article{Monath2016YellowFV,
  title={Yellow fever vaccine supply: a possible solution},
  author={Thomas Monath and John P. Woodall and Duane J. Gubler and Thomas M. Yuill and John S. Mackenzie and Reinaldo de Menezes Martins and Paul Reiter and David L. Heymann},
  journal={The Lancet},
  year={2016},
  volume={387},
  pages={1599-1600}
}
Boosting Global Yellow Fever Vaccine Supply for Epidemic Preparedness: 3 Actions for China and the USA
TLDR
These vaccines could be made available nationally, regionally, and globally through the ICG, e.g., to help stop and prevent epidemics anywhere in the world.
A high-throughput neutralization assay for yellow fever serodiagnostics
TLDR
A novel fluorescence-based serum neutralization test (SNTFLUO) with equally high sensitivity and specificity that is fit for processing large number of samples in a highly standardized manner and has the potential to be implemented in clinical use is presented.
Re-thinking yellow fever vaccines: fighting old foes with new generation vaccines
TLDR
The live-attenuated vaccine’s limitations are reviewed and the epitome of a yellow fever vaccine is explored, whilst scrutinizing next-generation vaccine candidates.
The Risks of Yellow Fever to Asian Primates
TLDR
It is found that Malaysia, Singapore, Indonesia, Brunei, and portions of southern India are high-risk zones for the occurrence of the YF virus, and that Asian primates can become particularly vulnerable if theYF virus is introduced into the region.
Yellow fever in Asia–a risk analysis
TLDR
Despite the rise in air travel, there is low support for travel patterns between YF endemic countries and Asia resulting in autochthonous transmission during 2016, which supports the historic absence of YF in Asia and suggests it could be due to a limited number of introductions in previous years.
Eliminating yellow fever epidemics in Africa: Vaccine demand forecast and impact modelling
TLDR
By estimating YF burden and vaccine impact over a range of spatial and temporal scales, while accounting for the specificity of urban transmission, a model can be used to inform the current EYE strategy.
Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomized, double-blind, non-inferiority trial
TLDR
These results support fractional dosing of all WHO-prequalified yellow fever vaccines for the general adult population for outbreak response in situations of vaccine shortage.
...
1
2
3
4
...

References

SHOWING 1-7 OF 7 REFERENCES
Subdoses of 17DD yellow fever vaccine elicit equivalent virological/immunological kinetics timeline
TLDR
Analysis of serum biomarkers IFN-γ and IL-10, in association to PRNT and viremia, support the recommendation of use of a ten-fold lower subdose (3,013 IU) of 17DD-YF vaccine.
17DD yellow fever vaccine
TLDR
In young healthy adults Bio-Manguinhos/Fiocruz yellow fever vaccine can be used in much lower doses than usual, and is as immunogenic and safe as the current formulation.
Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years.
TLDR
Based on currently available data, a single dose of YF vaccine is highly immunogenic and confers sustained life-long protective immunity against YF, and a booster dose is not needed.
Yellow fever vaccination: The potential of dose-sparing to increase vaccine supply and availability.
TLDR
An assessment of which settings would be most appropriate and to what extent novel ID delivery devices such as needle-free disposable-syringe jet injectors would help to facilitate its successful implementation of dose-sparing as a vaccine delivery strategy is included.
Urban yellow fever epidemic in western Nigeria, 1987.